These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 27569084)

  • 1. Silybin nanoparticles for liver cancer: development, optimization and in vitro - in vivo evaluation.
    Zhang H; Wang CB; Liu JL
    J BUON; 2016; 21(3):633-44. PubMed ID: 27569084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of silybin nanoparticles in mice bearing SKOV-3 human ovarian carcinoma xenocraft.
    Guan XL; Zhao SZ; Hou RJ; Yang SH; Zhang QL; Yin SL; Wang SJ
    Int J Clin Exp Med; 2015; 8(10):17406-17. PubMed ID: 26770331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eudragit nanoparticles loaded with silybin: a detailed study of preparation, freeze-drying condition and in vitro/in vivo evaluation.
    Varshosaz J; Minaiyan M; Khaleghi N
    J Microencapsul; 2015; 32(3):211-23. PubMed ID: 25561026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on the preparation and bio-distribution of silybin lipid nanospheres].
    Xu XM; Li Q; Zhu Y; Shen S; Shen Z; Yu JN
    Zhongguo Zhong Yao Za Zhi; 2005 Dec; 30(24):1912-4. PubMed ID: 16494021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer.
    Golla K; Bhaskar C; Ahmed F; Kondapi AK
    J Cancer; 2013; 4(8):644-52. PubMed ID: 24155776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery.
    Wang Y; Zhang D; Liu Z; Liu G; Duan C; Jia L; Feng F; Zhang X; Shi Y; Zhang Q
    Nanotechnology; 2010 Apr; 21(15):155104. PubMed ID: 20332565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies.
    Jia L; Zhang D; Li Z; Duan C; Wang Y; Feng F; Wang F; Liu Y; Zhang Q
    Colloids Surf B Biointerfaces; 2010 Oct; 80(2):213-8. PubMed ID: 20621458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc oxide nanoparticles as a novel anticancer approach; in vitro and in vivo evidence.
    Hassan HF; Mansour AM; Abo-Youssef AM; Elsadek BE; Messiha BA
    Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):235-243. PubMed ID: 27718258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered silybin nanoparticles educe efficient control in experimental diabetes.
    Das S; Roy P; Pal R; Auddy RG; Chakraborti AS; Mukherjee A
    PLoS One; 2014; 9(7):e101818. PubMed ID: 24991800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Targeting Albumin-Coated Silybin-Phospholipid Particles Prepared by Nab™ Technology for Improving Treatment Effect of Acute Liver Damage in Intravenous Administration.
    Lu C; Li X; Liang X; Zhang X; Yin T; Gou J; He H; Zhang Y; Tang X
    AAPS PharmSciTech; 2019 Aug; 20(7):293. PubMed ID: 31432294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo effect of paclitaxel and cepharanthine co-loaded polymeric nanoparticles in gastric cancer.
    Yu HH; Mi WN; Liu B; Zhao HP
    J BUON; 2016; 21(1):125-34. PubMed ID: 27061540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of N-nitrosodiethylamine induced hepatocarcinogenesis by silymarin in rats.
    Ramakrishnan G; Raghavendran HR; Vinodhkumar R; Devaki T
    Chem Biol Interact; 2006 Jun; 161(2):104-14. PubMed ID: 16643877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs.
    Cao X; Deng W; Fu M; Zhu Y; Liu H; Wang L; Zeng J; Wei Y; Xu X; Yu J
    Eur J Pharm Sci; 2013 Jan; 48(1-2):64-71. PubMed ID: 23123331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, formula optimization and antitumor actions of mannitol coupling camptothecin nanoparticles.
    Wang Z; Li Q; Zhao X; Sun B; Zhu Q; Gao W; Hua C
    Int J Pharm; 2014 Apr; 465(1-2):360-7. PubMed ID: 24530520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles.
    Jiang S; Gong X; Zhao X; Zu Y
    Drug Deliv; 2015 Feb; 22(2):206-13. PubMed ID: 24471890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma.
    Qian C; Idoate M; Bilbao R; Sangro B; Bruña O; Vázquez J; Prieto J
    Hum Gene Ther; 1997 Feb; 8(3):349-58. PubMed ID: 9048202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma.
    Feng N; Wu P; Li Q; Mei Y; Shi S; Yu J; Xu J; Liu Y; Wang Y
    J Drug Target; 2008 Jul; 16(6):479-85. PubMed ID: 18604660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility.
    Duan RL; Sun X; Liu J; Gong T; Zhang ZR
    Acta Pharmacol Sin; 2011 Jan; 32(1):108-15. PubMed ID: 21170082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the nanotechnology-based drug delivery of Silybin.
    Wang Y; Zhang L; Wang Q; Zhang D
    J Biomed Nanotechnol; 2014 Apr; 10(4):543-58. PubMed ID: 24734507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.